Friday, September 29, 2006

Athenagen Raises $50M

South San Francisco-based biopharmaceutical firm Athenagen has raised $50M in a Series B funding, the firm said Thursday. The funding was co-led by Sanderling Ventures and Clarus Ventures. Index Ventuers, Charter Life Sciences, and Astelles Venture Management also particpated in the funding round. The funding will be used to advance development of the company's lead programs targeting Alzheimer's disease, age-related macular degeneration (AMD) and cognition enhancement. More information »